{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:28:40Z","timestamp":1740180520874,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"crossref","award":["2014\/09079-1"],"award-info":[{"award-number":["2014\/09079-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"crossref","award":["303379\/2018-9"],"award-info":[{"award-number":["303379\/2018-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Faculdade de Medicina da USP - SP","award":["."],"award-info":[{"award-number":["."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The protein chitinase-3-like-1 (YKL-40) is rarely analyzed in patients with myositis. Therefore, we aimed to evaluate YKL-40 serum levels; correlate them with laboratory and clinical parameters, disease status, and treatment schemes; and analyze the YKL-40 expression in the muscle tissues of patients with antisynthetase syndrome (ASSD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This cross-sectional single-center study included 64 adult patients with ASSD who were age-, gender-, and ethnicity-matched to 64 healthy control individuals. Their YKL-40 serum levels were analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA) kit method, while YKL-40 expression in muscle tissues was analyzed using an immunohistochemical technique. Disease status was assessed using the International Myositis Assessment and Clinical Studies Group (IMACS) set scores.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The patients\u2019 mean age was 44.8\u2009\u00b1\u200911.8\u2009years, and median disease duration was 1.5 (0.0\u20134.0) years. These patients were predominantly female (82.8%) and Caucasian (73.4%). Most patients had stable disease. The median YKL-40 serum level was significantly higher in patients with ASSD when compared to the healthy individuals: 538.4 (363.4\u2013853.1) pg\/mL versus 270.0 (201.8\u2013451.9) pg\/mL, respectively; <jats:italic>P<\/jats:italic>\u00a0&lt;\u20090.001. However, YKL-40 serum levels did not correlate with any clinical, laboratory, disease status, or therapeutic parameters (<jats:italic>P<\/jats:italic>\u00a0&gt;\u20090.050), except tumor necrosis factor alpha (TNF-\u03b1) serum levels (Spearman\u2019s correlation, <jats:italic>rho<\/jats:italic>\u00a0=\u20090.382; <jats:italic>P<\/jats:italic>\u00a0=\u20090.007). YKL-40 was highly expressed by inflammatory cells found in muscle biopsy specimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>High YKL-40 serum levels were observed in patients with ASSD and correlated positively with TNF-\u03b1 serum levels. Moreover, YKL-40 was expressed by the inflammatory cells of the muscle tissue.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-021-00199-z","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T13:03:13Z","timestamp":1625490193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["High YKL-40 serum levels and its expression in the muscle tissues of patients with antisynthetase syndrome"],"prefix":"10.1186","volume":"61","author":[{"given":"Renata Casseb de Souza","family":"Carboni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo Luiz","family":"Behrens Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3682-4517","authenticated-orcid":false,"given":"Samuel Katsuyuki","family":"Shinjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"issue":"6","key":"199_CR1","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","volume":"138","author":"GR Connors","year":"2010","unstructured":"Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest. 2010;138(6):1464\u201374. https:\/\/doi.org\/10.1378\/chest.10-0180.","journal-title":"Chest."},{"issue":"11","key":"199_CR2","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.3390\/jcm8112013","volume":"8","author":"L Cavagna","year":"2019","unstructured":"Cavagna L, Trallero-Aragu\u00e1s E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, et al. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med. 2019;8(11):2013. https:\/\/doi.org\/10.3390\/jcm8112013.","journal-title":"J Clin Med"},{"issue":"5","key":"199_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1590\/S0482-50042010000500003","volume":"50","author":"SK Shinjo","year":"2010","unstructured":"Shinjo SK, Levy-Neto M. Anti-Jo-1 antisynthetase syndrome. Rev Bras Reumatol. 2010;50(5):492\u2013500. https:\/\/doi.org\/10.1590\/S0482-50042010000500003.","journal-title":"Rev Bras Reumatol"},{"issue":"1","key":"199_CR4","first-page":"44","volume":"36","author":"MA Gonz\u00e1lez-Gay","year":"2018","unstructured":"Gonz\u00e1lez-Gay MA, Montecucco C, Selva-O\u2019Callaghan A, Trallero-Aragua E, Molberg O, Andersson H, et al. Timing of onset affects arthritis presentation pattern in antisyntethase syndrome. Clin Exp Rheumatol. 2018;36(1):44\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"34","key":"199_CR5","doi-asserted-by":"publisher","first-page":"25803","DOI":"10.1016\/S0021-9258(19)74461-5","volume":"268","author":"BE Hakala","year":"1993","unstructured":"Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem. 1993;268(34):25803\u201310. https:\/\/doi.org\/10.1016\/S0021-9258(19)74461-5.","journal-title":"J Biol Chem"},{"issue":"4","key":"199_CR6","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1006\/bbrc.2001.5253","volume":"285","author":"F De Ceuninck","year":"2001","unstructured":"De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun. 2001;285(4):926\u201331. https:\/\/doi.org\/10.1006\/bbrc.2001.5253.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"199_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-physiol-012110-142250","volume":"73","author":"CG Lee","year":"2011","unstructured":"Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, et al. Role of chitin and chitinase\/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011;73(1):479\u2013501. https:\/\/doi.org\/10.1146\/annurev-physiol-012110-142250.","journal-title":"Annu Rev Physiol"},{"issue":"7","key":"199_CR8","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.cellsig.2013.03.016","volume":"25","author":"M Prakash","year":"2013","unstructured":"Prakash M, Bodas M, Prakash D, Nawani N, Khetmalas M, Mandal A, et al. Diverse pathological implications of YKL-40: answers may lie in \u2018outside-in\u2019 signaling. Cell Signal. 2013;25(7):1567\u201373. https:\/\/doi.org\/10.1016\/j.cellsig.2013.03.016.","journal-title":"Cell Signal"},{"issue":"1","key":"199_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1515\/folmed-2017-0013","volume":"59","author":"MH Kazakova","year":"2017","unstructured":"Kazakova MH, Batalov AZ, Mateva NG, Sarafian VS. YKL-40 and cytokines-a new diagnostic constellation in rheumatoid arthritis? Folia Med. 2017;59(1):37\u201342. https:\/\/doi.org\/10.1515\/folmed-2017-0013.","journal-title":"Folia Med"},{"issue":"1","key":"199_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/147323000903700102","volume":"37","author":"K Huang","year":"2009","unstructured":"Huang K, Wu LD. YKL-40: a potential biomarker for osteoarthritis. J Int Med Res. 2009;37(1):18\u201324. https:\/\/doi.org\/10.1177\/147323000903700102.","journal-title":"J Int Med Res"},{"issue":"7","key":"199_CR11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/rheumatology\/38.7.618","volume":"38","author":"JS Johansen","year":"1999","unstructured":"Johansen JS, Stoltenberg M, Hansen M, Florescu A, Horslev-Petersen K, Lorenzen I, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford). 1999;38(7):618\u201326. https:\/\/doi.org\/10.1093\/rheumatology\/38.7.618.","journal-title":"Rheumatology (Oxford)"},{"key":"199_CR12","first-page":"92","volume":"10","author":"MR Jafari-Nakhjavani","year":"2019","unstructured":"Jafari-Nakhjavani MR, Ghorbanihaghjo A, Bagherzadeh-Nobari B, Malek-Mahdavi A, Rashtchizadeh N. Serum YKL-40 levels and disease characteristics in patients with rheumatoid arthritis. Caspian J Int Med. 2019;10:92\u20137.","journal-title":"Caspian J Int Med"},{"key":"199_CR13","doi-asserted-by":"publisher","first-page":"e0183294","DOI":"10.1371\/journal.pone.0183294","volume":"12","author":"T V\u00e4\u00e4n\u00e4nen","year":"2017","unstructured":"V\u00e4\u00e4n\u00e4nen T, Vuolteenaho K, Kautiainen H, Nieminen R, Mottonen T, Hannonen P, et al. NEO-RACo Study Group. Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. PLoS One. 2017;12:e0183294.","journal-title":"PLoS One"},{"issue":"5","key":"199_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s002960100115","volume":"20","author":"R Peltomaa","year":"2001","unstructured":"Peltomaa R, Paimela L, Harvey S, Helve T, Leirisalo-Repo M. Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int. 2001;20(5):192\u20136. https:\/\/doi.org\/10.1007\/s002960100115.","journal-title":"Rheumatol Int"},{"issue":"12","key":"199_CR15","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1002\/1529-0131(199912)42:12<2624::AID-ANR17>3.0.CO;2-K","volume":"42","author":"JS Johansen","year":"1999","unstructured":"Johansen JS, Baslund B, Garbarsch C, Hansen M, Stoltenberg M, Lorenzen I, et al. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum. 1999;42(12):2624\u201330. https:\/\/doi.org\/10.1002\/1529-0131(199912)42:12<2624::AID-ANR17>3.0.CO;2-K.","journal-title":"Arthritis Rheum"},{"key":"199_CR16","first-page":"2147","volume":"30","author":"GL Montagna","year":"2003","unstructured":"Montagna GL, D\u2019Angelo S, Valentini G. Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease. Rheumatolology. 2003;30:2147\u201351.","journal-title":"Rheumatolology."},{"issue":"4","key":"199_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/03009740510018598","volume":"34","author":"C Nordenbaek","year":"2005","unstructured":"Nordenbaek C, Johansen JS, Halberg P, Wiik A, Garbarsch C, Ullman S, et al. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol. 2005;34(4):293\u20137. https:\/\/doi.org\/10.1080\/03009740510018598.","journal-title":"Scand J Rheumatol"},{"key":"199_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ijcard.2019.06.058","volume":"293","author":"Y Sun","year":"2019","unstructured":"Sun Y, Kong X, Wu S, Ma L, Yan Y, Lv P, et al. YKL-40 as a new biomarker of disease activity in Takayasu arteritis. Int J Cardiol. 2019;293:231\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2019.06.058.","journal-title":"Int J Cardiol"},{"issue":"9","key":"199_CR19","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3899\/jrheum.170373","volume":"44","author":"H Hozumi","year":"2017","unstructured":"Hozumi H, Fujisawa T, Enomoto N, Nakashima R, Enomoto Y, Suzuki Y, et al. Clinical utility of YKL-40 in polymyositis\/dermatomyositis-associated interstitial lung disease. J Rheumatol. 2017;44(9):1394\u2013401. https:\/\/doi.org\/10.3899\/jrheum.170373.","journal-title":"J Rheumatol"},{"issue":"1","key":"199_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/0004563218786979","volume":"56","author":"MZ Gao","year":"2019","unstructured":"Gao MZ, Wei YY, Xu QW, Ji R, Han Z-J, Jian T-W, et al. Elevated serum YKL-40 correlates with clinical characteristics in patients with polymyositis or dermatomyositis. Ann Clin Biochem. 2019;56(1):95\u20139. https:\/\/doi.org\/10.1177\/0004563218786979.","journal-title":"Ann Clin Biochem"},{"issue":"6","key":"199_CR21","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s10067-019-04457-w","volume":"38","author":"L Jiang","year":"2019","unstructured":"Jiang L, Wang Y, Peng Q, Shu X, Wang G, Wu X, et al. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. Clin Rheumatol. 2019;38(6):1655\u201363. https:\/\/doi.org\/10.1007\/s10067-019-04457-w.","journal-title":"Clin Rheumatol"},{"key":"199_CR22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","volume":"68","author":"MG Cruellas","year":"2013","unstructured":"Cruellas MG, Viana V dos S, Levy-Neto M, FHC DS, Shinjo SK. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics. 2013;68:909\u201314.","journal-title":"Clinics"},{"issue":"3","key":"199_CR23","first-page":"603","volume":"30","author":"LG Rider","year":"2003","unstructured":"Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. International myositis assessment and clinical studies group. Defining clinical improvement in adult and juvenile myositis. J Rheumatol. 2003;30(3):603\u201317.","journal-title":"J Rheumatol"},{"issue":"11","key":"199_CR24","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1002\/art.1780401109","volume":"40","author":"LG Rider","year":"1997","unstructured":"Rider LG, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB, Zemel LS, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. physician, parent, and patient global assessments. Juvenile dermatomyositis disease activity collaborative study group. Arthritis Rheum. 1997;40(11):1976\u201383. https:\/\/doi.org\/10.1002\/art.1780401109.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"199_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/rheumatology\/ken441","volume":"48","author":"MO Harris-Love","year":"2009","unstructured":"Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis, and juvenile dermatomyositis. Rheumatology (Oxford). 2009;48(2):134\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/ken441.","journal-title":"Rheumatology (Oxford)"},{"key":"199_CR26","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","volume":"40","author":"FW Miller","year":"2001","unstructured":"Miller FW, Rider GL, Chung YL, et al. International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2001;40:1262\u201373.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"199_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","volume":"1","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries JF. The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1(1):20. https:\/\/doi.org\/10.1186\/1477-7525-1-20.","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"199_CR28","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.ejrad.2016.05.012","volume":"85","author":"Y Waseda","year":"2016","unstructured":"Waseda Y, Johkoh T, Egashira R, Sumikawa H, Saeki K, Watanabe S, et al. Antisynthetase syndrome: pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases. Eur J Radiol. 2016;85(8):1421\u20136. https:\/\/doi.org\/10.1016\/j.ejrad.2016.05.012.","journal-title":"Eur J Radiol"},{"issue":"3","key":"199_CR29","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","volume":"84","author":"MP Debray","year":"2015","unstructured":"Debray MP, Borie R, Revel MP, Naccache J-M, Khalil A, Toper C, et al. Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. Eur J Radiol. 2015;84(3):516\u201323. https:\/\/doi.org\/10.1016\/j.ejrad.2014.11.026.","journal-title":"Eur J Radiol"},{"issue":"8","key":"199_CR30","first-page":"1545","volume":"33","author":"KE Sada","year":"2006","unstructured":"Sada KE, Yamasaki Y, Maruyama M, Sugiyama H, Yamamura M, Maeshima Y, et al. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol. 2006;33(8):1545\u201352.","journal-title":"J Rheumatol"},{"issue":"3","key":"199_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/08916930600622256","volume":"39","author":"S Salomonsson","year":"2006","unstructured":"Salomonsson S, Lundberg IE. Cytokines in idiopathic inflammatory myopathies. Autoimmunity. 2006;39(3):177\u201390. https:\/\/doi.org\/10.1080\/08916930600622256.","journal-title":"Autoimmunity."},{"issue":"1","key":"199_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0165-5728(95)00122-0","volume":"63","author":"I Lundberg","year":"1995","unstructured":"Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol. 1995;63(1):9\u201316. https:\/\/doi.org\/10.1016\/0165-5728(95)00122-0.","journal-title":"J Neuroimmunol"},{"issue":"6","key":"199_CR33","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1097\/BOR.0000000000000653","volume":"31","author":"L Gallay","year":"2019","unstructured":"Gallay L, Mouchiroud G, Chazaud B. Interferon-signature in idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2019;31(6):634\u201342. https:\/\/doi.org\/10.1097\/BOR.0000000000000653.","journal-title":"Curr Opin Rheumatol"},{"key":"199_CR34","first-page":"35","volume":"34","author":"C Hou","year":"2018","unstructured":"Hou C, Baba-Amer Y, Bencze M, Relaix F, Authier FJ. The effect of interferon-gamma on skeletal muscle cell biology. Med Sci. 2018;34:35\u20138.","journal-title":"Med Sci"},{"issue":"8","key":"199_CR35","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00296-017-3729-y","volume":"37","author":"K Isoda","year":"2017","unstructured":"Isoda K, Kotani T, Takeuchi T, Kiboshi T, Hata K, Ishida T, et al. Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus antimelanoma differentiation-associated gene 5 antibody. Rheumatol Int. 2017;37(8):1335\u201340. https:\/\/doi.org\/10.1007\/s00296-017-3729-y.","journal-title":"Rheumatol Int"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-021-00199-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-021-00199-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-021-00199-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T13:03:25Z","timestamp":1625490205000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-021-00199-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["199"],"URL":"https:\/\/doi.org\/10.1186\/s42358-021-00199-z","relation":{},"ISSN":["2523-3106"],"issn-type":[{"type":"electronic","value":"2523-3106"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"11 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local ethics committee (CAAE: 89386618.0.0000.0068) and all participants signed the informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}